Gowhari Shabgah [123] shows that utilizing IL-25-enhancing approaches, such as Virulizin® (mixture of proteins and peptides as immune response modifiers) and dihydrobenzofuran administration, has potentially inhibited tumor cell growth in cancers in which IL-25 has a tumor-suppressive function. This evidence concerns the gene IL25 and neoplasm.